[go: up one dir, main page]

IL130424A - Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis - Google Patents

Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis

Info

Publication number
IL130424A
IL130424A IL13042496A IL13042499A IL130424A IL 130424 A IL130424 A IL 130424A IL 13042496 A IL13042496 A IL 13042496A IL 13042499 A IL13042499 A IL 13042499A IL 130424 A IL130424 A IL 130424A
Authority
IL
Israel
Prior art keywords
preparation
ziprasidone
medicaments
compositions
hydrochloride monohydrate
Prior art date
Application number
IL13042496A
Other languages
English (en)
Other versions
IL130424A0 (en
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL130424(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL130424A0 publication Critical patent/IL130424A0/xx
Publication of IL130424A publication Critical patent/IL130424A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
  • Detergent Compositions (AREA)
IL13042496A 1998-06-15 1999-06-10 Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis IL130424A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (2)

Publication Number Publication Date
IL130424A0 IL130424A0 (en) 2000-06-01
IL130424A true IL130424A (en) 2003-10-31

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13042496A IL130424A (en) 1998-06-15 1999-06-10 Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis

Country Status (44)

Country Link
US (1) US6150366A (fr)
EP (1) EP0965343B1 (fr)
JP (2) JP3441676B2 (fr)
KR (1) KR100338915B1 (fr)
CN (1) CN1307994C (fr)
AP (1) AP1216A (fr)
AR (1) AR015553A1 (fr)
AT (1) ATE240732T1 (fr)
AU (1) AU753820B2 (fr)
BG (1) BG64691B1 (fr)
BR (1) BR9902268A (fr)
CA (1) CA2274338C (fr)
CO (1) CO5070579A1 (fr)
CY (1) CY2003002I1 (fr)
CZ (1) CZ297954B6 (fr)
DE (1) DE69908021T2 (fr)
DK (1) DK0965343T3 (fr)
EA (1) EA002223B1 (fr)
ES (1) ES2197581T3 (fr)
GT (1) GT199900080A (fr)
HN (1) HN1999000089A (fr)
HR (1) HRP990193B1 (fr)
HU (1) HU226487B1 (fr)
ID (1) ID23546A (fr)
IL (1) IL130424A (fr)
IS (1) IS2182B (fr)
MA (1) MA26647A1 (fr)
MY (1) MY121397A (fr)
NO (1) NO316713B1 (fr)
NZ (1) NZ336271A (fr)
OA (1) OA11064A (fr)
PA (1) PA8475601A1 (fr)
PE (1) PE20000632A1 (fr)
PL (2) PL195209B1 (fr)
PT (1) PT965343E (fr)
RS (1) RS49611B (fr)
SG (1) SG77243A1 (fr)
SI (1) SI0965343T1 (fr)
SK (1) SK286245B6 (fr)
TR (1) TR199901379A2 (fr)
TW (1) TW590774B (fr)
UA (1) UA59383C2 (fr)
UY (1) UY25649A1 (fr)
ZA (1) ZA993938B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
EA003907B1 (ru) * 1999-05-27 2003-10-30 Пфайзер Продактс Инк. Композиция зипразидона в виде суспензии
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230875B1 (hu) 2000-10-30 2018-11-29 Euro-Celtique S.A. Szabályozott hatóanyag-leadású hidrokodon készítmények
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
EP2301537A1 (fr) * 2002-05-17 2011-03-30 Duke University Zonisamide pour le traitement de l'obésité
WO2004050655A1 (fr) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Formes polymorphes de ziprasidone et son chlorhydrate
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
DK2316456T3 (en) * 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
KR20060015750A (ko) * 2003-06-03 2006-02-20 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
WO2005040160A2 (fr) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Procedes de preparation de ziprasidone
WO2005054235A1 (fr) * 2003-11-28 2005-06-16 Wockhardt Limited Procede de preparation de ziprasidone monochlorhydrate hydrate
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (fr) * 2004-01-13 2006-12-27 Duke University Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
US20080312254A1 (en) * 2004-02-27 2008-12-18 Ranbaxy Laboratories Limited Process for the Preparation of Ziprasidone
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
WO2005107719A2 (fr) * 2004-05-06 2005-11-17 Sandoz Ag Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
CA2467538C (fr) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
CA2471219A1 (fr) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Preparation amelioree d'une forme anhydre du chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one (chlorhydrate de ziprasidone)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
RU2007106036A (ru) 2004-08-31 2008-10-10 Пфайзер Продактс Инк. (Us) Антитело к cd40: препарат и способы
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
WO2006086779A1 (fr) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Ziprasidone mesylate amorphe
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (fr) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Synthese de sels d'addition acide de ziprasidone et de produits intermediaires connexes au moyen de reactions solide-gaz
WO2006098834A2 (fr) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Formes cristallines de mesylate de ziprasidone
WO2006099452A1 (fr) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Mesylate de ziprasidone anhydre et son procede de preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
KR20070119678A (ko) * 2005-04-13 2007-12-20 화이자 프로덕츠 인코포레이티드 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법
AU2006239900A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CN102048734B (zh) 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
WO2007027273A1 (fr) * 2005-06-20 2007-03-08 Elan Pharma International Limited Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (fr) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Formes polymorphes de sels de sulfate de ziprasidone
EP1889844A3 (fr) * 2006-08-02 2008-03-05 Krka Formes polymorphiques de sulfates de ziprasidone
AU2007319471B9 (en) 2006-11-09 2012-10-04 Nalpropion Pharmaceuticals Llc Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US20080286373A1 (en) * 2007-05-18 2008-11-20 Palepu Nageswara R Ziprasidone formulations
EP2197446A4 (fr) * 2007-08-31 2012-01-25 Reddys Lab Ltd Dr Préparation de chlorhydrate de ziprasidone monohydraté
WO2009116085A2 (fr) * 2008-03-11 2009-09-24 Alkem Laboratories Ltd. Procédé amélioré de préparation de ziprasidone
CA2725930A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procedes pour traiter des pathologies des graisses viscerales
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
WO2010151711A1 (fr) 2009-06-25 2010-12-29 Alkermes, Inc. Promédicaments de composés nh acides
EP2340834A1 (fr) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Solubilité améliorée de la ziprasidone
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
EP2538925B1 (fr) 2010-02-25 2015-12-16 Bristol-Myers Squibb Company Formulations d'apixaban
WO2011148253A2 (fr) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Formes posologiques solides d'antipsychotiques
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
KR20210012056A (ko) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT790236E (pt) * 1996-02-13 2004-04-30 Pfizer Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada

Also Published As

Publication number Publication date
AU3398399A (en) 1999-12-23
KR100338915B1 (ko) 2002-05-30
IL130424A0 (en) 2000-06-01
CN1242987A (zh) 2000-02-02
BR9902268A (pt) 2000-05-02
SK286245B6 (sk) 2008-06-06
DE69908021D1 (de) 2003-06-26
PL195209B1 (pl) 2007-08-31
UA59383C2 (uk) 2003-09-15
NO316713B1 (no) 2004-04-13
PL333737A1 (en) 1999-12-20
CZ297954B6 (cs) 2007-05-09
JP4187423B2 (ja) 2008-11-26
CZ212799A3 (cs) 2000-09-13
PA8475601A1 (es) 2000-09-29
HK1024184A1 (en) 2000-10-05
US6150366A (en) 2000-11-21
CN1307994C (zh) 2007-04-04
SG77243A1 (en) 2000-12-19
JP3441676B2 (ja) 2003-09-02
ATE240732T1 (de) 2003-06-15
CY2003002I1 (el) 2009-11-04
JP2000007566A (ja) 2000-01-11
GT199900080A (es) 2000-11-29
ES2197581T3 (es) 2004-01-01
EP0965343B1 (fr) 2003-05-21
HN1999000089A (es) 1999-11-03
AR015553A1 (es) 2001-05-02
NO992892D0 (no) 1999-06-14
DE69908021T2 (de) 2003-11-27
ID23546A (id) 2000-05-04
PE20000632A1 (es) 2000-07-26
CA2274338A1 (fr) 1999-12-15
ZA993938B (en) 2000-12-14
CA2274338C (fr) 2003-04-15
CO5070579A1 (es) 2001-08-28
RS49611B (sr) 2007-06-04
IS5079A (is) 1999-12-16
SK76999A3 (en) 2000-12-11
AP1216A (en) 2003-10-19
HU9901960D0 (en) 1999-08-30
BG103489A (en) 2000-07-31
TR199901379A2 (xx) 2000-01-21
EA199900467A2 (ru) 1999-12-29
NZ336271A (en) 2000-10-27
AP9901579A0 (en) 1999-06-30
TW590774B (en) 2004-06-11
HUP9901960A3 (en) 2000-09-28
AU753820B2 (en) 2002-10-31
OA11064A (en) 2002-03-13
UY25649A1 (es) 2000-02-23
MA26647A1 (fr) 2004-12-20
HRP990193A2 (en) 2000-02-29
KR20000006143A (ko) 2000-01-25
BG64691B1 (bg) 2005-12-30
HU226487B1 (en) 2009-03-02
EP0965343A3 (fr) 2000-02-23
YU27199A (sh) 2002-12-10
EP0965343A2 (fr) 1999-12-22
PT965343E (pt) 2003-08-29
NO992892L (no) 1999-12-16
SI0965343T1 (en) 2003-10-31
EA199900467A3 (ru) 2000-04-24
MY121397A (en) 2006-01-28
EA002223B1 (ru) 2002-02-28
PL195606B1 (pl) 2007-10-31
HUP9901960A2 (hu) 2000-08-28
DK0965343T3 (da) 2003-08-04
HRP990193B1 (en) 2003-08-31
IS2182B (is) 2006-12-15
JP2002003492A (ja) 2002-01-09

Similar Documents

Publication Publication Date Title
IL130424A (en) Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
IL193615A0 (en) New azaindoles for inhibiting protein kinases and pharmaceutical composition comprising the same
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
AU4468201A (en) External preparation for the skin and beautifying agents
HUP0202897A3 (en) Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them
HUS1300061I1 (hu) Herbicid kompozíció
IL155071A0 (en) Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
IL158076A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
HUP0103851A3 (en) Factor viia inhibitors, process for their preparation, their use and pharmaceutical compositions comprising thereof
HUP0202648A3 (en) Imidazolyl derivatives, pharmaceutical compositions containing them and their use
HUP0200155A3 (en) Thioamide derivatives, pharmaceutical compositions containing them and their use
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
HUP0102585A3 (en) Thienylazolylalcoxyethanamin derivatives preparation the same and their use as medicaments
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
HUP0200441A3 (en) Tetrahydropyran derivatives and their use as therapeutic agents and process for preparation the compounds
HUP9803040A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
HUP0204449A3 (en) Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
IL145520A0 (en) Flame-retarding composition and process for the preparation thereof
HUT76052A (en) Azole derivatives having adhesion-receptor antagonistic effect, process for their preparation and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees